文献速递前列腺癌

哥德堡-1随机人群前列腺癌筛查试验中的前列腺特异性抗原检测与活检污染情况

Prostate Specific Antigen and Biopsy Contamination in the Göteborg-1 Randomized, Population-Based, Prostate Cancer Screening Trial.
PubMed 文献 · J Urol · 2022-06-30

哥德堡-1随机人群试验纳入50-64岁男性20000人,1994年随机分为筛查组(每2年检测前列腺特异性抗原)与对照组,随访至2014年12月31日。结果显示对照组72%至少检测1次前列腺特异性抗原(污染),筛查组87%;筛查组66%在抗原升高后12个月内接受前列腺活检,对照组28%。作者认为规范筛查较非规范检测更有效降低前列腺癌死亡率。

要点

  • 对照组72%至少检测1次前列腺特异性抗原(污染),筛查组87%。
  • 筛查组66%在抗原升高后12个月内接受前列腺活检,对照组28%。
  • 作者认为规范筛查较非规范检测更有效降低前列腺癌死亡率。

核心结论

  • 筛查组与对照组接受前列腺特异性抗原检测的比例相近,但仅少数污染性前列腺特异性抗原检测导致活检。
  • 筛查组男性开始筛查的年龄更年轻,这两点可能解释规范筛查较非规范检测更有效降低前列腺癌死亡率。
  • 若规范实施并与未筛查人群比较,规范筛查的效果可能比哥德堡筛查试验既往所示更大。

研究设计与样本

  • 哥德堡-1随机人群前列腺癌筛查试验,1994年邀请50-64岁男性20000人,随机分为筛查组(每2年检测前列腺特异性抗原)与对照组,随访至2014年12月31日。
  • 结局指标为筛查组与对照组的总体检测情况,前列腺特异性抗原阳性定义为≥3 ng/ml。

主要发现

  • 研究开始前,筛查组4.2%、对照组4.6%的男性已接受检测。
  • 随访期间,对照组72%至少接受1次前列腺特异性抗原检测(污染),筛查组为87%。
  • 全部前列腺特异性抗原检测中,筛查组24%、对照组39%高于阈值。
  • 筛查组66%的男性在前列腺特异性抗原升高后12个月内接受前列腺活检,对照组为28%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Even when a screening study has demonstrated a mortality reduction, the degree of pre-testing and contamination is of importance as it can dilute the "true" effect of screening. Our object was to describe the level of pre-testing and contamination in the Göteborg-1 prostate cancer screening trial. MATERIALS AND METHODS: A total of 20,000 men, 50-64 years old, were invited in 1994 and randomized to either a screening group (offered prostate specific antigen testing every 2 years) or to a control group. Follow-up was through December 31, 2014. Outcome measurement was overall testing in the screening group and control group. A positive prostate specific antigen test was defined as a prostate specific antigen ≥3 ng/ml. RESULTS: In the study, 4.2% in the screening group and 4.6% men in the control group were tested before study start. During follow-up, 72% in the control group took at least 1 prostate specific antigen test (contamination) compared to 87% of men in the screening group. Of all prostate specific antigens, 24% in the screening group and 39% in the control group were above threshold. In total, 66% of the men underwent prostate biopsy within 12 months from a raised prostate specific antigen in the screening group and 28% in the control group. CONCLUSIONS: Similar proportions of men were prostate specific antigen-tested in both the screening group and control group, yet only a minority of contamination prostate specific antigens led to biopsy. Also, men in the screening group started screening at a younger age. These could both be explanations for our result that organized screening is more effective in reducing prostate cancer mortality than non-organized testing. When carried out properly and compared to an unscreened population, the effects of organized screening are likely even greater than previously shown in the Göteborg screening trial.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Stinesen Kollberg K, Holmberg E, Josefsson A, et al. Prostate Specific Antigen and Biopsy Contamination in the Göteborg-1 Randomized, Population-Based, Prostate Cancer Screening Trial. J Urol. 2022. PMID: 35771961. doi:10.1097/JU.0000000000002835

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。